Holen Sie sich die Stockscreener-App
2.12
0.93%
-0.02
Handel nachbörslich:
2.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.14
Offen:
$2.09
24-Stunden-Volumen:
10.39M
Relative Volume:
0.71
Marktkapitalisierung:
$767.13M
Einnahmen:
$241.53M
Nettoeinkommen (Verlust:
$-389.92M
KGV:
-1.7236
EPS:
-1.23
Netto-Cashflow:
$-323.54M
1W Leistung:
-2.75%
1M Leistung:
-6.61%
6M Leistung:
-37.83%
1J Leistung:
-78.30%
1-Tages-Spanne:
$2.09
$2.19
1-Wochen-Bereich:
$2.04
$2.34
52-Wochen-Spanne:
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.12 | 774.37M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Identifying reversal signals in Iovance Biotherapeutics Inc.Weekly Market Report & Daily Technical Forecast Reports - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfoliosJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
Why Iovance Biotherapeutics Inc. stock appeals to analystsGlobal Markets & Daily Chart Pattern Signal Reports - newser.com
Is Iovance Biotherapeutics Inc. stock a good choice for value investorsJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Iovance Biotherapeutics Inc. stock prediction for this weekEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
Why Iovance Biotherapeutics Inc. stock is favored by top institutionsQuarterly Profit Report & Daily Growth Stock Tips - newser.com
Does Iovance Biotherapeutics Inc. stock trade at a discount to peersWeekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? - AOL.com
Signal strength of Iovance Biotherapeutics Inc. stock in tech scannersInsider Selling & Smart Allocation Stock Tips - newser.com
Using R and stats models for Iovance Biotherapeutics Inc. forecastingJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Iovance: Q3 Earnings May Smart, But Long Term Bull Thesis Remains In Play (IOVA) - Seeking Alpha
How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stockGap Up & High Yield Stock Recommendations - newser.com
Using flow based indicators on Iovance Biotherapeutics Inc.July 2025 PostEarnings & Reliable Price Breakout Alerts - newser.com
Real time breakdown of Iovance Biotherapeutics Inc. stock performanceJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock signals breakout potential - newser.com
Iovance Biotherapeutics (NASDAQ:IOVA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Is Iovance Biotherapeutics Inc. (2LB) stock positioned for digital growth eraMarket Sentiment Summary & Daily Chart Pattern Signal Reports - newser.com
Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.7%What's Next? - MarketBeat
Iovance Biotherapeutics Inc Stock Analysis and ForecastIndustrial Stocks Review & Stay Ahead With Daily Market Discussions - earlytimes.in
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.5%Should You Sell? - MarketBeat
Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance
Will Iovance Biotherapeutics Inc. rebound enough to break evenAnalyst Downgrade & Safe Entry Trade Signal Reports - newser.com
Will Iovance Biotherapeutics Inc. (2LB) stock announce special dividendMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com
What the Recent 11% Surge Means for Iovance Biotherapeutics Stock in 2025 - Sahm
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Iovance Biotherapeutics (IOVA) Valuation in Focus After Recent Share Price Gains - Sahm
How Iovance Biotherapeutics Inc. stock performs during Fed tightening cyclesShort Setup & Capital Efficient Trade Techniques - newser.com
Analyzing Iovance Biotherapeutics Inc. with multi timeframe chartsJuly 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Puri Raj K. | Chief Regulatory Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
5,470 |
0 |
215,324 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,697 |
0 |
111,857 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 02 '25 |
Option Exercise |
0.00 |
12,306 |
0 |
105,939 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Jun 05 '25 |
Buy |
1.84 |
30,000 |
55,200 |
30,000 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
5,469 |
0 |
212,321 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 02 '25 |
Option Exercise |
0.00 |
52,085 |
0 |
426,731 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,695 |
0 |
105,608 |
| BILINSKY IGOR | Chief Operating Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
12,305 |
0 |
99,883 |
| Bellemin Jean-Marc | Chief Financial Officer |
Jun 02 '25 |
Option Exercise |
0.00 |
8,789 |
0 |
64,993 |
| Puri Raj K. | Chief Regulatory Officer |
May 23 '25 |
Buy |
1.74 |
5,600 |
9,743 |
206,852 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):